Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to UAU201313715UpriorityCriticalpatent/UA86173U/en
Publication of UA86173UpublicationCriticalpatent/UA86173U/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
The method for treating the hypertensive nephropathy comprises the use of the blocker of rennin-angiotensin-aldosteron system and antagonist of calcium channels. Alisciren is used at a dose of 300 mg once a day. Lercanidipin is used at a dose of 10 mg once a day.
UAU201313715U2013-11-252013-11-25Method for treating hypertensive nephropathy
UA86173U
(en)